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Kaposi's sarcoma-associated herpesvirus (KSHV) is a
human DNA tumor virus etiologically linked to Kaposi's
sarcoma, primary effusion lymphoma, and a subset of
multicentric Castleman's disease. Infection and reactiva-
tion of KSHV activates multiple MAPK pathways. Notice-
ably, the ERK/RSK activation is sustained late during
KSHV primary infection and reactivation from latency,
but the responsible viral factors and underlying mecha-
nism was unknown. Open reading frame 45 (ORF45) of
KSHV is an immediate early, phosphorylated, and tegu-
ment protein. Its unique temporal and spatial expression
put it in the forefront of coping with host cellular environ-
ment. We recently reported that ORF45 interacts with p90
ribosomal S6 kinases (RSKs), a family of serine/threonine
kinases that lie at the terminus of the ERK pathway, and
strongly stimulates their kinase activities. We found that
binding of ORF45 to RSK increases the association of ERK
with RSK, such that ORF45, RSK, and ERK form com-
plexes. The complexes shield active pERK and pRSK from
dephosphorylation. As a result, the complex-associated
RSK and ERK are activated and sustained at high levels.
We also demonstrated that RSK and ERK are activated
biphasically during KSHV primary infection and lytic rep-
lication cycle. We provided evidence that the reciprocal
activation of ERK and RSK by ORF45 contributes to the
sustained activation of ERK/RSK in KSHV lytic replication.
We further demonstrated that ablation of RSK expression
by SiRNA or inhibition of kinase activity by specific RSK
inhibitors lead to lower KSHV lytic gene expression, reac-
tivation, and virus production, suggesting an essential role
of the RSK in KSHV lytic replication. Therefore, inhibition
of RSK is likely to disrupt KSHV infection and be a potent
target for therapy of KSHV associated diseases.
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